PBEF/NAMPT/visfatin: A promising drug target for treating rheumatoid arthritis?

Future Medicinal Chemistry

Volumn 4, Issue 6, 2012, Pages 751-769

  Nowell, Mari ^a   Evans, Laura ^a   Williams, Anwen ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (7 BROMO 3,4 DIHYDRO 2 METHYL 4 OXO 6 QUINAZOLINYLMETHYL) N (2 PROPYNYL)AMINO] N (3 PYRIDYLMETHYL)BENZAMIDE; [[N (7 BROMO 3,4 DIHYDRO 2 METHYL 4 OXOQUINAZOLIN 6 YLMETHYL) N (PROP 2 YNYL)AMINO] N (3 PYRIDYLMETHYL)BENZAMIDE]; AMENTOTAXUS BIFLAVONE; ANTIRHEUMATIC AGENT; DAPORINAD; FLAVONE DERIVATIVE; GMX 1778; JIN SONG BIFLAVONE; MPC 9528; MPI 0487316; N (6 CHLOROPHENOXYHEXYL) N' CYANO N' 4 PYRIDYLGUANIDINE; N [4 (1 BENZOYLPEPERIDIN 4 YL)BUTYL] 3 (1H PYRROL 2 YL)ACRYLAMIDE; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' (4 PYRIDYL)GUANIDINE; NICOTINAMIDE; NICOTINAMIDE NUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SIRTUIN; TANNIN; UNCLASSIFIED DRUG;

ARTICLE; BIOSYNTHESIS; CELL STRUCTURE; CIRCULATION; DRUG INHIBITION; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; IC 50; IN VIVO STUDY; INFLAMMATION; LEUKOCYTE; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIUM;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SIGNAL TRANSDUCTION;

EID: 84860246717     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.34     Document Type: Article

References (125)

1. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell. Biol. 14(2), 1431-1437 (1994).
2. Martin PR, Shea RJ, Mulks MH. Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence. J. Bacteriology 183(4), 1168-1174 (2001).
3. Rongvaux A, She RJ, Mulks MH et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur. J. Immunol. 32(11), 3225-3234 (2002).
4. Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: A protein secreted by visceral fat that Mimics the effects of insulin. Science 307(5708), 426-430 (2005).
5. Li Y, Zhang Y, Dorweiler B et al. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J. Biol. Chem. 283(50), 34833-34843 (2008).
6. Moschen AR, Kaser A, Enrich B et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 178(3), 1748-1758 (2007).
7. Imai S. The NAD World: A new systemic regulatory network for metabolism and aging - Sirt1, systemic NAD biosynthesis, and their importance. Cell Biochem. Biophys. 53(2), 65-74 (2009).
8. Garten A, Petzold S, Korner A, Imai S, Kiess W. Nampt: Linking NAD biology, metabolism and cancer. Trends Endocrinol. Metab. 20(3), 130-138 (2009).
9. Chaput M, Claes V, Portetelle D et al. The neurotrophic factor neuroleukin is 90% homologous with phosphohexose isomerase. Nature 332(6163), 454-455 (1988).
10. Xu Q, Leiva MC, Fischkoff SA, Handschumacher RE, Lyttle CR. Leukocyte chemotactic activity of cyclophilin. J. Biol. Chem. 267(17), 11968-11971 (1992).
11. Hoogewerf AJ, Leone JW, Reardon IM et al. CXC chemokines connective tissue activating peptide-III and neutrophil activating peptide-2 are heparin/heparan sulfate-degrading enzymes. J. Biol. Chem. 270(7), 3268-3277 (1995).
12. Swope M, Sun HW, Blake PR, Lolis E. Direct link between cytokine activity and a catalytic site for macrophage migration inhibitory factor. EMBO J. 17(13), 3534-3541 (1998).
13. Bogan KL, Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: A molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu. Rev. Nutr. 28, 115-130 (2008).
14. Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease. Trends Biochem. Sci. 32(1), 12-19 (2007).
15. Pfefferkorn ER, Rebhun S, Eckel M. Characterization of an indoleamine 2,3-dioxygenase induced by gamma-interferon in cultured human fibroblasts. J. Interferon Res. 6(3), 267-279 (1986).
16. Nowell MA, Richards PJ, Fielding CA et al. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: Implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 54(7), 2084-2095 (2006).
17. Patrone L, Damore MA, Lee MB, Malone CS, Wall R. Genes expressed during the IFNg induced maturation of pre-B cells. Mol. Immunol. 38(8), 597-606 (2002).
18. Ognjanovic S, Bao S, Yamamoto SY, Garibay-Tupas J, Samal B, Bryant-Greenwood GD. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J. Mol. Endocrinol. 26(2), 107-117 (2001).
19. Nemeth E, Tashima LS, Yu Z, Bryant-Greenwood GD. Fetal membrane distention: I. Differentially expressed genes regulated by acute distention in amniotic epithelial (WISH) cells. Am. J. Obstet. Gynecol. 182(1 Pt 1), 50-59 (2000).
20. Bae SK, Kim SR, Kim JG et al. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett. 580(17), 4105-4113 (2006).
21. Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P. Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science 324(5927), 654-657 (2009).
22. Yang H, Yang T, Baur JA et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 130(6), 1095-1107 (2007).
23. Pillai JB, Isbatan A, Imai S, Gupta MP. Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity. J. Biol. Chem. 280(52), 43121-43130 (2005).
24. Fulco M, Cen Y, Zhao P et al. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev. Cell 14(5), 661-673 (2008).
25. Van Der Veer E, Nong Z, O'Neil C, Urquhart B, Freeman D, Pickering JG. Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circulation Res. 97(1), 25-34 (2005).
26. Rongvaux A, Galli M, Denanglaire S et al. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J. Immunol. 181(7), 4685-4695 (2008).
27. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J. Biol. Chem. 279(49), 50754-50763 (2004).
28. Tak PP, Zvaifler NJ, Green DR, Firestein GS. Rheumatoid arthritis and p53: How oxidative stress might alter the course of inflammatory diseases. Immunol. Today 21(2), 78-82 (2000).
29. Whittle JR, Powell MJ, Popov VM, Shirley LA, Wang C, Pestell RG. Sirtuins, nuclear hormone receptor acetylation and transcriptional regulation. Trends Endocrinol. Metab. 18(9), 356-364 (2007).
30. Smith J. Human Sir2 and the 'silencing' of p53 activity. Trends Cell Biol. 12(9), 404-406 (2002).
31. Niederer F, Ospelt C, Brentano F et al. SIRT1 overexpression in the rheumatoid arthritis synovium contributes to proinflammatory cytokine production and apoptosis resistance. Ann. Rheum. Dis. 70(10), 1866-1873 (2011).
32. Grabiec AM, Krausz S, de Jager W et al. Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J. Immunol. 184(5), 2718-2728 (2010).
33. Dvir-Ginzberg M, Gagarina V, Lee EJ, Hall DJ. Regulation of cartilage-specific gene expression in human chondrocytes by SirT1 and nicotinamide phosphoribosyltransferase. J. Biol. Chem. 283(52), 36300-36310 (2008).
34. Hong EH, Yun HS, Kim J et al. Nicotinamide phosphoribosyltransferase is essential for interleukin-1beta-mediated dedifferentiation of articular chondrocytes via SIRT1 and extracellular signal-regulated kinase (ERK) complex signaling. J. Biol. Chem. 286(32), 28619-28631 (2011).
35. Van Gool F, Galli M, Gueydan C et al. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat. Med. 15(2), 206-210 (2009).
36. Bruzzone S, Fruscione F, Morando S et al. Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLoS One 4(11), e7897 (2009).
37. Skokowa J, Lan D, Thakur BK et al. NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. Nat. Med. 15(2), 151-158 (2009).
38. Revollo JR, Korner A, Mills KF et al. Nampt/PBEF/visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 6(5), 363-375 (2007).
39. Friebe D, Neef M, Kratzsch J et al. Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia 54(5), 1200-1211 (2011).
40. Brentano F, Schorr O, Ospelt C et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arth. Rheum. 56(9), 2829-2839 (2007).
41. Berndt J, KlÖting N, Kralisch S et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54(10), 2911-2916 (2005).
42. Revollo JR, Grimm AA, Imai SI. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr. Opin. Gastroenterol. 23(2), 164-170 (2007).
43. Curat CA, Wegner V, Sengenes C et al. Macrophages in human visceral adipose tissue: Increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 49(4), 744-747 (2006).
44. Jia SH, Li Y, Parodo J et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J. Clin. Invest. 113(9), 1318-1327 (2004).
45. Yonezawa T, Haga S, Kobayashi Y, Takahashi T, Obara Y. Visfatin is present in bovine mammary epithelial cells, lactating mammary gland and milk, and its expression is regulated by cAMP pathway. FEBS Lett. 580(28-29), 6635-6643 (2006).
46. Garten A, Petzold S, Barnikol-Oettler A et al. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem. Biophys. Res. Commun. 391(1), 376-381 (2009).
47. Tanaka M, Nozaki M, Fukuhara A et al. Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. Biochem. Biophys. Res. Commun. 359(2), 194-201 (2007).
48. Jin H, Jiang B, Tang J et al. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res. Clin. Pract. 79(3), 412-418 (2008).
49. Moschen AR, Gerner R, Schroll A, Fritz T, Kaser A, Tilg H. A key role for pre-B-cell colony-enhancing factor in experimental hepatitis. Hepatology 54(2), 675-686 (2011).
50. Chung CP, Long AG, Solus JF et al. Adipocytokines in systemic lupus erythematosus: Relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus 18(9), 799-806 (2009).
51. Ye SQ, Simon BA, Maloney JP et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am. J. Respir. Crit. Care Med. 171(4), 361-370 (2005).
52. Axelsson J, Witasp A, Carrero JJ et al. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am. J. Kidney Dis. 49(2), 237-244 (2007).
53. Otero M, Lago R, Gomez R et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann. Rheumatic Dis. 65(9), 1198-1201 (2006).
54. Wiest R, Leidl F, Kopp A et al. Peritoneal fluid adipokines: Ready for prime time? Eur. J. Clin. Invest. 39(3), 219-229 (2009).
55. Mazaki-Tovi S, Romero R, Kusanovic JP et al. Visfatin/pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: An association with subclinical intrauterine infection in preterm parturition. J. Perinat. Med. 36(6), 485-496 (2008).
56. Hallschmid M, Randeva H, Tan BK, Kern W, Lehnert H. Relationship between cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity in humans. Diabetes 58(3), 637-640 (2009).
57. Rho YH, Solus J, Sokka T et al. Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum. 60(7), 1906-1914 (2009).
58. Senolt L, Krystufkova O, Hulejova H et al. The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy. Cytokine 55(1), 116-121 (2011).
59. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Garcia-Unzueta MT et al. Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-Alpha therapy. Clin. Exp. Rheumatol. 28(1), 56-62 (2010).
60. Matsui H, Tsutsumi A, Sugihara M et al. Visfatin (pre-B cell colony-enhancing factor) gene expression in patients with rheumatoid arthritis. Ann. Rheumatic Dis. 67(4), 571-572 (2008).
61. Mesko B, Poliska S, Szegedi A et al. Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets. BMC Med. Genomics 3, 15 (2010).
62. Iqbal J, Zaidi M. TNF regulates cellular NAD+ metabolism in primary macrophages. Biochem. Biophys. Res. Comm. 342(4), 1312-1318 (2006).
63. Schilling E, Wehrhahn J, Klein C, Raulien N, Ceglarek U, Hauschildt S. Inhibition of nicotinamide phosphoribosyltransferase modifies LPS-induced inflammatory responses of human monocytes. Innate Immun. doi:10.1177/ 1753425911428553 (2011) (Epub ahead of print).
64. Dahl TB, Yndestad A, Skjelland M et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: Possible role in inflammation and plaque destabilization. Circulation 115(8), 972-980 (2007).
65. Chen MP, Chung FM, Chang DM et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 91(1), 295-299 (2006).
66. Olesen UH, Hastrup N, Sehested M. Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas. APMIS 119(4-5), 296-303 (2011).
67. Shackelford RE, Bui MM, Coppola D, Hakam A. Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers. Int. J. Clin. Exp. Pathol. 3(5), 522-527 (2010).
68. Hufton SE, Moerkerk PT, Brandwijk R, De Bruïne AP, Arends JW, Hoogenboom HR. A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett. 463(1-2), 77-82 (1999).
69. Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: Parallel increase in plasma visfatin. J. Clin. Endocrinol. Metab. 91(12), 5022-5028 (2006).
70. Ognjanovic S, Bryant-Greenwood GD. Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. Am. J. Obstet. Gynecol. 187(4), 1051-1058 (2002).
71. Ozgen M, Koca SS, Aksoy K, Dagli N, Ustundag B, Isik A. Visfatin levels and intima-media thicknesses in rheumatic diseases. Clin. Rheumatol. 30(6), 757-763 (2010).
72. Vadacca M, Margiotta D, Rigon A et al. Adipokines and systemic lupus erythematosus: Relationship with metabolic syndrome and cardiovascular disease risk factors. J. Rheumatol. 36(2), 295-297 (2009).
73. Zifzaf D, Kaddah E, El Bakri S, ElZaher A, Abo-Shady R. Pre-B Cell Colony-enhancing factor as a marker of erosions in rheumatoid arthritis patients. Life Sci. J. 8(4), 628-634 (2011).
74. Evans L, Williams AS, Hayes AJ, Jones SA, Nowell M. Suppression of leukocyte infiltration and cartilage degradation by selective inhibition of pre-B cell colony-enhancing factor/visfatin/nicotinamide phosphoribosyltransferase: Apo866-mediated therapy in human fibroblasts and murine collagen-induced arthritis. Arthritis Rheum. 63(7), 1866-1877 (2011).
75. Gosset M, Berenbaum F, Salvat C et al. Crucial role of visfatin/pre-B cell colony-enhancing factor in matrix degradation and prostaglandin E2 synthesis in chondrocytes: Possible influence on osteoarthritis. Arthritis Rheum. 58(5), 1399-1409 (2008).
76. Yammani RR, Loeser RF Jr. Extracellular nicotinamide phosphoribosyltransferase (NAMPT/visfatin) inhibits insulin-like growth factor-1 signaling and proteoglycan synthesis in human articular chondrocytes. Arthritis Res. Ther. 14(1), R23 (2011).
77. Li Y, He X, He J, Anderstam B, Andersson G, Lindgren U. Nicotinamide phosphoribosyltransferase (Nampt) affects the lineage fate determination of mesenchymal stem cells: A possible cause for reduced osteogenesis and increased adipogenesis in older individuals. J. Bone Miner. Res. 26(11), 2656-2664 (2011).
78. Cohen-Kfir E, Artsi H, Levin A et al. Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor. Endocrinology 152(12), 4514-4524 (2011).
79. Shaffer AL, Rosenwald A, Hurt EM et al. Signatures of the immune response. Immunity 15(3), 375-385 (2001).
80. Malam Z, Parodo J, Waheed F, Szaszi K, Kapus A, Marshall JC. Pre-B cell colony-enhancing factor (PBEF/Nampt/visfatin) primes neutrophils for augmented respiratory burst activity through partial assembly of the NADPH oxidase. J. Immunol. 186(11), 6474-6484 (2011).
81. Moschen AR, Geiger S, Gerner R, Tilg H. Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. Mutat Res, 690(1-2), 95-101 (2010).
82. Fox EJ, Gibson M, Zhang LQ, Leeder JS, Ye SQ, Becker ML. Decreased Expression of nicotinamide phosphoribosyltransferase (NAMPT) in active juvenile idiopathic arthritis patients receiving methotrexate. Presented at: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting. Chicago, IL, USA 4-9 November 2011.
83. Herenius M, Klaasen R, de Jager W, Prakken BJ, Gerlag D, Tak PP. Anti-TNF therapy reduces adipocytokine levels and improves the lipid profile in patients with rheumatoid arthritis: A possible mechanism contributing to lowered cardiovascular risk. Presented at: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting. Atlanta, GA, USA 6-11 November 2010.
84. Hoffer A. Treatment of arthritis by nicotinic acid and nicotinamide. Can. Med. Assoc. J. 81, 235-238 (1959).
85. Stratford MR, Rojas A, Hall DW et al. Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers. Radiother. Oncol. 25(1), 37-42 (1992).
86. Wosikowski K, Mattern K, Schemainda I, Hasmann M, Rattel B, Loser R. WK175, a novel anti-Tumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells. Cancer Res. 62(4), 1057-1062 (2002).
87. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 63(21), 7436-7442 (2003).
88. Drevs J, Loser R, Rattel B, Esser N. Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res. 23(6C), 4853-4858 (2003).
89. Muruganandham M, Alfieri AA, Matei C et al. Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin. Cancer Res. 11(9), 3503-3513 (2005).
90. Holen K, Saltz L, Hollywood E, Burk K, Hanauske A. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest. New Drugs 26(1), 45-51 (2008).
91. Evans LE, Williams AS, Hayes AJ, Jones SA, Nowell MA. Selective inhibition of PBEF/Visfatin/NAMPT supresses leukocyte infiltration and cartilage degradation. Arthritis Rheum. 63(7), 1866-1877 (2011).
92. Busso N, Karababa M, Nobile M et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One 3(5), e2267 (2008).
93. Khan JA, Tao X, Tong L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat. Struct. Mol. Biol. 13(7), 582-588 (2006).
94. Kim MK, Lee JH, Kim H et al. Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866. J. Mol. Biol. 362(1), 66-77 (2006).
95. Chappie JS, Canaves JM, Han GW, Rife CL, Xu Q, Stevens RC. The structure of a eukaryotic nicotinic acid phosphoribosyltransferase reveals structural heterogeneity among type II PRTases. Structure 13(9), 1385-1396 (2005).
96. Irmler IM, Opfermann T, Gebhardt P et al. In vivo molecular imaging of experimental joint inflammation by combined (18)F-FDG positron emission tomography and computed tomography. Arthritis Res. Ther. 12(6), R203 (2010).
97. Hovstadius P, Larsson R, Jonsson E et al. A Phase I study of CHS 828 in patients with solid tumor malignancy. Clin. Cancer Res. 8(9), 2843-2850 (2002).
98. Ravaud A, Cerny T, Terret C et al. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: An ECSG/EORTC study. Eur. J. Cancer 41(5), 702-707 (2005).
99. von Heideman A, Berglund Ö, Larsson R, Nygren P. Safety and efficacy of NAD depleting cancer drugs: Results of a Phase I clinical trial of CHS 828 and overview of published data. Cancer Chemother. Pharmacol. 65(6), 1165-1172 (2010).
100. Olesen UH, Thougaard AV, Jensen PB, Sehested M. A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. Mol. Cancer Ther. 9(6), 1609-1617 (2010).
101. Hjarnaa PJ, Jonsson E, Latini S et al. CHS 828, a novel pyridyl cyanoguanidine with potent anti-Tumor activity in vitro and in vivo. Cancer Res. 59(22), 5751-5757 (1999).
102. Fleischer TC, Baichwal VR, Boniface JJ et al. Coadministration of nicotinic acid with the Nampt inhibitor MPC-9528 enhances anti-Tumor activity in Naprt deficient cancer cells in culture and in xenografts. Presented at: AACR 102nd Annual Meeting. Orlando, FL, USA 2-6 April 2011.
103. Galli U, Ercolano E, Carraro L et al. Synthesis and biological evaluation of isosteric analogs of FK866, an inhibitor of NAD salvage. ChemMedChem 3(5), 771-779 (2008).
104. Kang GB, Bae MH, Kim MK, Im I, Kim YC, Eom SH. Crystal structure of Rattus norvegicus visfatin/PBEF/Nampt in complex with an FK866-based inhibitor. Molecules and Cells 27(6), 667-671 (2009).
105. You H, Youn H-S, Im I et al. Design, synthesis and x-ray crystallographic study of NAmPRTase inhibitors as anti-cancer agents. Eur. J. Med. Chem. 46(4), 1153-1164 (2011).
106. Schou C, Ottosen ER, Petersen HJ et al. Novel cyanoguanidines with potent oral anti-Tumor activity. Bioorg. Med. Chem. Lett. 7(24), 3095-3100 (1997).
107. Vig Hjarnaa P-J, Jonsson E, Latini S et al. CHS 828, a novel pyridyl cyanoguanidine with potent anti-Tumor activity in vitro and in vivo. Cancer Res. 59(22), 5751-5757 (1999).
108. Jonsson E, Friberg LE, Karlsson MO et al. In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumor cells from patients. Cancer Lett. 162(2), 193-200 (2001).
109. Aleskog A, Bashir-Hassan S, Hovstadius P et al. Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro. Anticancer Drugs 12(10), 821-827 (2001).
110. Watson M, Roulston A, Blec L et al. The Small Molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: Strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol. Cell. Biol. 29(21), 5872-5888 (2009).
111. Fuchs D, Rodriguez A, Eriksson S, Christofferson R, Sundberg C, Azarbayjani F. Metronomic administration of the drug GMX1777, a cellular NAD synthesis inhibitor, results in neuroblastoma regression and vessel maturation without inducing drug resistance. Intl J. Cancer 126(12), 2773-2789 (2010).
112. Skelton LA, Ormerod MG, Titley JC, Jackman AL. Cell cycle effects of CB30865, a lipophilic quinazoline-based analog of the antifolate thymidylate synthase inhibitor ICI 198583 with an undefined mechanism of action. Cytometry 33(1), 56-66 (1998).
113. Skelton LA, Ormerod MG, Titley J, Kimbell R, Brunton LA, Jackman AL. A novel class of lipophilic quinazoline-based folic acid analogs: Cytotoxic agents with a folate-independent locus. Br. J. Cancer 79(11-12), 1692-1701 (1999).
114. Fleischer TC, Murphy BR, Flick JS et al. Chemical proteomics identifies nampt as the target of CB30865, an orphan cytotoxic compound. Chem. Biol. 17(6), 659-664 (2010).
115. Lockman JW, Murphy BR, Zigar DF et al. Analogs of 4-[(7-Bromo-2-methyl-4- oxo-3H-quinazolin-6-yl)methylprop-2-ynylamino]-N-(3-pyridylmethyl)benzamide (CB-30865) as potent inhibitors of nicotinamide phosphoribosyltransferase (Nampt). J. Med.Chem. 53(24), 8734-8746 (2010).
116. Fleischer TC, Baichwal VR, Bradford CL et al. MPI-0486348: A novel inhibitor of nicotinamide phosphoribosyltransferase induces tumor regression in a preclinical model. Presented at: AACR 101st Annual Meeting. Washington DC, USA 17-21 April 2010.
117. Zhang R-Y, Qin Y, Lv X-Q et al. A fluorometric assay for high-Throughput screening targeting nicotinamide phosphoribosyltransferase. Anal. Biochem. 412(1), 18-25 (2011).
118. Huang WY, Cai YZ, Zhang Y. Natural phenolic compounds from medicinal herbs and dietary plants: Potential use for cancer prevention. Nutr. Cancer 62(1), 1-20 (2010).
119. Olesen UH, Petersen JG, Garten A et al. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase. BMC Cancer 10, 677 (2010).
120. Isaacs JD. Therapeutic T-cell manipulation in rheumatoid arthritis: Past, present and future. Rheumatology (Oxford) 47(10), 1461-1468 (2008).
121. 4+ T cells. Clin. Exp. Immunol. 148(2), 288-295 (2007).
122. Liptay S, Fulda S, Schanbacher M et al. Molecular mechanisms of sulfasalazine-induced T-cell apoptosis. Br. J. Pharmacol. 137(5), 608-620 (2002).
123. Fleischer TC, Flick JS, Terry-Lorenzo RT et al. Identifying the target of an orphan compound: CB30865 is a Nampt inhibitor. Presented at: AACR 101st Annual Meeting. Washington DC, USA, 17-21 April 2010.
124. Boniface JJ, Baichwal VR, Cimbora DM et al. Basal NAD levels and Nampt expression correlate with in vitro and in vivo sensitivity of tumor cell lines to the Nampt inhibitor MPC09528. Presented at: AACR 102nd Annual Meeting. Orlando, FL, USA, 2-6 April 2011.
125. Carlson RO, Willardsen JA, Lockman JW et al. Pharmacokinetics, anti-Tumor activity and therapeutic index of Nampt inhibitor MPC-8640 in mice. Presented at: AACR-NCI-EORTC International Conference. San Francisco, CA, USA, 12-16 November 2011.